Who are TAK-816's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Propafenone i.v., Flecainide controlled release, Medium-dose anrikefon, Flecainide Injectable Solution, SHR6390 Tablets, USL255.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tak-816.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

TAK-816 — Competitive Intelligence Brief

TAK-816 (TAK-816) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium-activated potassium channel inhibitor. Area: Cardiovascular.

phase 3 Sodium-activated potassium channel inhibitor Nav1.5 Cardiovascular Biologic Live · refreshed every 30 min

Target snapshot

TAK-816 (TAK-816) — Takeda. TAK-816 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TAK-816 TARGET	TAK-816	Takeda	phase 3	Sodium-activated potassium channel inhibitor	Nav1.5
Propafenone i.v.	Propafenone i.v.	Charles University, Czech Republic	marketed	Class IC antiarrhythmic agent	Cardiac sodium channel (Nav1.5)
Flecainide controlled release	Flecainide controlled release	MEDA Pharma GmbH & Co. KG	marketed	Class IC antiarrhythmic agent	Cardiac voltage-gated sodium channel (Nav1.5)
Medium-dose anrikefon	Medium-dose anrikefon	Peking University First Hospital	marketed	Sodium channel blocker	Nav1.5
Flecainide Injectable Solution	Flecainide Injectable Solution	Hippocration General Hospital	phase 3	Class IC antiarrhythmic agent	Cardiac voltage-gated sodium channel (Nav1.5)
SHR6390 Tablets	SHR6390 Tablets	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Sodium-activated potassium channel inhibitor	Nav1.5
USL255	USL255	Upsher-Smith Laboratories	phase 3	sodium-activated potassium channel inhibitor	Nav1.5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium-activated potassium channel inhibitor class)

Chiesi Farmaceutici S.p.A. · 1 drug in this class
Chong Kun Dang Pharmaceutical · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Mylan Inc. · 1 drug in this class
Pfizer · 1 drug in this class
Syndeio Biosciences, Inc · 1 drug in this class
Takeda · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TAK-816 — Competitive Intelligence Brief. https://druglandscape.com/ci/tak-816. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab